Stockscreener 앱 받기
1.60
3.61%
-0.06
전일 마감가:
$1.66
열려 있는:
$1.67
하루 거래량:
982.96K
Relative Volume:
0.85
시가총액:
$193.39M
수익:
$257.24M
순이익/손실:
$-237.89M
주가수익비율:
-0.6154
EPS:
-2.6
순현금흐름:
$-175.17M
1주 성능:
-5.33%
1개월 성능:
+15.11%
6개월 성능:
+77.78%
1년 성능:
+12.68%
1일 변동 폭
$1.59
$1.67
1주일 범위
$1.56
$1.72
52주 변동 폭
$0.71
$1.89
Coherus Oncology Inc Stock (CHRS) Company Profile
명칭
Coherus Oncology Inc
전화
(650) 649-3530
주소
C/O DENNIS M. LANFEAR, REDWOOD CITY, CA
CHRS을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
CHRS
Coherus Oncology Inc
|
1.60 | 200.65M | 257.24M | -237.89M | -175.17M | -2.60 |
|
VRTX
Vertex Pharmaceuticals Inc
|
441.36 | 111.36B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
733.04 | 77.98B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
800.01 | 50.33B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
359.27 | 47.46B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
338.19 | 37.43B | 4.98B | 69.59M | 525.67M | 0.5197 |
Coherus Oncology Inc Stock (CHRS) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-09-04 | 업그레이드 | Maxim Group | Hold → Buy |
| 2024-08-16 | 다운그레이드 | UBS | Buy → Neutral |
| 2023-11-17 | 개시 | Robert W. Baird | Outperform |
| 2023-11-08 | 다운그레이드 | Maxim Group | Buy → Hold |
| 2023-07-24 | 개시 | Citigroup | Buy |
| 2023-05-01 | 개시 | Truist | Buy |
| 2023-03-28 | 업그레이드 | UBS | Neutral → Buy |
| 2022-06-14 | 개시 | UBS | Neutral |
| 2022-03-07 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2020-07-16 | 개시 | BofA Securities | Neutral |
| 2020-04-17 | 개시 | SunTrust | Buy |
| 2019-08-13 | 개시 | Mizuho | Buy |
| 2019-08-02 | 재확인 | H.C. Wainwright | Buy |
| 2019-08-02 | 재확인 | Maxim Group | Buy |
| 2019-06-11 | 개시 | Barclays | Overweight |
| 2019-05-07 | 개시 | H.C. Wainwright | Buy |
| 2018-08-28 | 개시 | H.C. Wainwright | Buy |
| 2018-03-09 | 재확인 | Maxim Group | Buy |
| 2017-08-08 | 재확인 | JP Morgan | Overweight |
| 2017-06-13 | 재확인 | Maxim Group | Buy |
| 2017-05-05 | 개시 | BMO Capital Markets | Outperform |
| 2016-10-19 | 개시 | Robert W. Baird | Outperform |
| 2016-09-07 | 개시 | Maxim Group | Buy |
| 2016-07-27 | 개시 | Citigroup | Buy |
| 2016-01-20 | 개시 | Credit Suisse | Outperform |
모두보기
Coherus Oncology Inc 주식(CHRS)의 최신 뉴스
Coherus Management to Present at the 44th Annual J.P. Morgan Healthcare Conference - 富途牛牛
Functional Force: Precision Platforms Disrupt the 2026 Tumor Landscape - The AI Journal
CHRS: Pivotal 2026 data readouts expected for innovative oncology assets, with sales growth on track - TradingView — Track All Markets
January 2026 Penny Stock Spotlight: Three Promising Picks - simplywall.st
Can Coherus Oncology Inc. (8C5) stock survive global slowdownDividend Hike & Growth Focused Entry Reports - Улправда
There's No Escaping Coherus Oncology, Inc.'s (NASDAQ:CHRS) Muted Revenues Despite A 27% Share Price Rise - simplywall.st
How Coherus Oncology Inc. (8C5) stock valuation compares with sectorOil Prices & Stepwise Swing Trade Plans - Улправда
Coherus Biosciences Divests UDENYCA Business - MSN
Coherus Oncology to Report Third Quarter 2025 Financial Results on November 6, 2025 - FinancialContent
Coherus publishes data on tagmokitug antibody for cancer treatment By Investing.com - Investing.com Nigeria
Coherus (CHRS) Reports Promising Results for Anti-CCR8 Antibody in Cancer Treatment - GuruFocus
Coherus Oncology Introduces Tagmokitug: Promising Results from CCR8-targeting Antibody Research - Quiver Quantitative
Coherus publishes data on tagmokitug antibody for cancer treatment - Investing.com
PRN_FinancialWrapper - FinancialContent
About Us - FinancialContent
What analysts say about Coherus Oncology Inc 8C5 stockMarket Insider Reports & Outstanding Growth Opportunities - earlytimes.in
Will Coherus Oncology Inc 8C5 stock outperform Dow Jones2025 Market Trends & Accurate Intraday Trading Signals - moha.gov.vn
Coherus Oncology (NASDAQ:CHRS) Share Price Passes Above 200 Day Moving AverageShould You Sell? - MarketBeat
Coherus Oncology (NASDAQ:CHRS) Stock Crosses Above Two Hundred Day Moving AverageHere's What Happened - MarketBeat
Coherus Oncology: A Two-Pronged March With Mid-2026 Implications (CHRS) - Seeking Alpha
Coherus Oncology, Inc.(NasdaqGM: CHRS) added to NASDAQ Biotechnology Index - marketscreener.com
Coherus Oncology (CHRS) price target increased by 13.33% to 5.78 - MSN
Coherus Oncology (CHRS) Price Target Increased by 13.33% to 5.78 - Nasdaq
Aug Shorts: How Coherus Oncology Inc. (8C5) stock valuation compares with sectorQuarterly Portfolio Review & AI Driven Stock Price Forecasts - Улправда
CEO Moves: How Coherus Oncology Inc. (8C5) stock valuation compares with sectorMarket Weekly Review & Risk Controlled Stock Pick Alerts - Улправда
Support Test: Can Coherus Oncology Inc. (8C5) stock survive global slowdownJuly 2025 Macro Moves & Smart Swing Trading Techniques - Улправда
Will Coherus Oncology Inc. (8C5) stock deliver stable dividends2025 Dividend Review & Breakout Confirmation Alerts - Улправда
CHRS: 2026 will be pivotal with major data readouts for novel immuno-oncology therapies - TradingView — Track All Markets
Coherus Oncology (NASDAQ:CHRS) Stock Price Crosses Above 200 Day Moving AverageTime to Sell? - MarketBeat
Coherus Oncology Earnings Notes - Trefis
LOQTORZI plus chemotherapy shows 31-month survival benefit in cancer study - Investing.com Australia
Coherus BioSciences stock jumps after positive cancer drug survival data By Investing.com - Investing.com UK
Coherus BioSciences stock jumps after positive cancer drug survival data - Investing.com
Coherus Announces Six-Year JUPITER-02 Follow-up Results Showing LOQTORZI® plus Chemotherapy Nearly Doubles Median Overall Survival in Nasopharyngeal Carcinoma - The Manila Times
Coherus Oncology (CHRS) price target decreased by 11.77% to 5.10 - MSN
Why Coherus Oncology Inc. (8C5) stock stays on top picksTrade Risk Summary & Daily Technical Forecast Reports - Newser
Why global investors buy Coherus Oncology Inc. (8C5) stockJuly 2025 Earnings & Expert Verified Movement Alerts - Newser
Does Coherus Oncology Inc. (8C5) stock trade below intrinsic valueMarket Volume Summary & Community Consensus Stock Picks - Newser
Why Coherus Oncology Inc. (8C5) stock could rally strongly2025 Trading Volume Trends & Free Safe Entry Trade Signal Reports - Newser
Can Coherus Oncology Inc. (8C5) stock sustain free cash flow2025 Macro Impact & AI Enhanced Trading Alerts - Newser
Coherus Oncology, Inc. (NASDAQ:CHRS) Looks Inexpensive After Falling 28% But Perhaps Not Attractive Enough - 富途牛牛
Can Coherus Oncology Inc. (8C5) stock hold up in economic slowdownTrade Risk Assessment & Fast Gain Stock Tips - Newser
How strong is Coherus Oncology Inc. (8C5) stock earnings growthAnalyst Downgrade & Safe Entry Zone Identification - Newser
Coherus Oncology (CHRS) Stock Analysis Report | Ratings, Financials & Performance - Benzinga
Is Coherus Oncology Inc 8C5 a good long term investmentEconomic Impact on Stocks & Build Wealth Brick by Brick With Us - earlytimes.in
Coherus Oncology Inc (CHRS) 재무 분석
매출
순이익
현금흐름
주당 순 이익
4.73%
0.92%
자본화:
|
볼륨(24시간):